The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yamawaki, Kengo ^a   Kondo, Yuichiro ^a   Okada, Tsutomu ^a   Oshima, Takeshi ^a   Kakitani, Makoto ^a   Tomizuka, Kazuma ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b RandD Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE PROSTHESIS; LIGAND; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL; BLOOD; BONE DISEASES; BONE NEOPLASMS; BONE PROSTHESIS; DISEASE MODEL; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MOUSE; OSTEOLYSIS; PATHOLOGY; SECONDARY; TRANSGENIC MOUSE;

ANIMALS; BONE DISEASES; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE NEOPLASMS; BONE SUBSTITUTES; DISEASE MODELS, ANIMAL; LIGANDS; MICE; MICE, TRANSGENIC; OSTEOLYSIS; PROTEIN BINDING; RECOMBINANT PROTEINS; X-RAY MICROTOMOGRAPHY;

EID: 84954567299     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18849     Document Type: Article

References (40)

1. Feng, X. H., Derynck, R. Specificity and versatility in tgf-beta signaling through Smads. Annual review of cell and developmental biology 21, 659-693, doi: 10.1146/annurev.cellbio.21.022404.142018 (2005).
2. Massague, J. TGF-beta signal transduction. Annual review of biochemistry 67, 753-791, doi: 10.1146/annurev.biochem.67.1.753 (1998).
3. Yamawaki, K. et al. Adult-specific systemic over-expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. PloS one 8, e78076, doi: 10.1371/journal.pone.0078076 (2013).
4. Chang, H., Brown, C. W., Matzuk, M. M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocrine reviews 23, 787-823 (2002).
5. Zhao, G. Q. Consequences of knocking out BMP signaling in the mouse. Genesis (New York, NY: 2000) 35, 43-56, doi: 10.1002/gene.10167 (2003).
6. Chantry, A. D. et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 25, 2633-2646, doi: 10.1002/jbmr.142 (2010).
7. Lee, S. J. et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences of the United States of America 102, 18117-18122, doi: 10.1073/pnas.0505996102 (2005).
8. Koncarevic, A. et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology 151, 4289-4300, doi: 10.1210/en.2010-0134 (2010).
9. Mitchell, D. et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Molecular cancer therapeutics 9, 379-388, doi: 10.1158/1535-7163.MCT-09-0650 (2010).
10. Baud'huin, M. et al. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. Proceedings of the National Academy of Sciences of the United States of America 109, 12207-12212, doi: 10.1073/pnas.1204929109 (2012).
11. Sherman, M. L. et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. Journal of clinical pharmacology 53, 1121-1130, doi: 10.1002/jcph.160 (2013).
12. Bendell, J. C. et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 480-489, doi: 10.1158/1078-0432.CCR-13-1840 (2014).
13. Attie, K. M. et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. American journal of hematology 89, 766-770, doi: 10.1002/ajh.23732 (2014).
14. Abdulkadyrov, K. M. et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. British Journal of Haematology 165, 814-823, doi: 10.1111/bjh.12835 (2014).
15. Mazerbourg, S. et al. Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses. The Journal of biological chemistry 280, 32122-32132, doi: 10.1074/jbc.M504629200 (2005).
16. Bragdon, B. et al. Bone morphogenetic proteins: a critical review. Cellular signalling 23, 609-620, doi: 10.1016/j.cellsig.2010.10.003 (2011).
17. Yoon, B. S. et al. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America 102, 5062-5067, doi: 10.1073/pnas.0500031102 (2005).
18. Edson, M. A. et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Molecular endocrinology (Baltimore, Md.) 24, 1251-1266, doi: 10.1210/me.2009-0461 (2010).
19. Pulkki, M. M. et al. A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cells. Endocrinology 153, 1509-1518, doi: 10.1210/en.2010-1390 (2012).
20. Sahni, V. et al. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 30, 1839-1855, doi: 10.1523/JNEUROSCI.4459-09.2010 (2010).
21. Kamiya, N. et al. Disruption of BMP Signaling in Osteoblasts Through Type IA Receptor (BMPRIA) Increases Bone Mass. Journal of Bone and Mineral Research 23, 2007-2017, doi: 10.1359/jbmr.080809 (2008).
22. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841, doi: 10.1038/nature02041 (2003).
23. Yi, S. E., Daluiski, A., Pederson, R., Rosen, V., Lyons, K. M. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127, 621-630 (2000).
24. Zhao, M. et al. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. The Journal of cell biology 157, 1049-1060, doi: 10.1083/jcb.200109012 (2002).
25. Hilton, M. J. et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nature medicine 14, 306-314, doi: 10.1038/nm1716 (2008).
26. Ann, E. J. et al. Inhibition of Notch1 signaling by Runx2 during osteoblast differentiation. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26, 317-330, doi: 10.1002/jbmr.227 (2011).
27. Kakitani, M. et al. A novel transgenic chimaeric mouse system for the rapid functional evaluation of genes encoding secreted proteins. Nucleic acids research 33, e85, doi: 10.1093/nar/gni083 (2005).
28. Kim, K. A. et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science (New York, NY) 309, 1256-1259, doi: 10.1126/science.1112521 (2005).
29. Yang, Y. A. et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. The Journal of clinical investigation 109, 1607-1615, doi: 10.1172/jci15333 (2002).
30. Schriefer, J. L. et al. A comparison of mechanical properties derived from multiple skeletal sites in mice. Journal of biomechanics 38, 467-475, doi: 10.1016/j.jbiomech.2004.04.020 (2005).
31. Howe, J. R. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. Journal of Medical Genetics 41, 484-491, doi: 10.1136/jmg.2004.018598 (2004).
32. Voorneveld, P. W. et al. Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. British journal of cancer 109, 1805-1812, doi: 10.1038/bjc.2013.486 (2013).
33. Bleuming, S. A. et al. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer research 67, 8149-8155, doi: 10.1158/0008-5472.CAN-06-4659 (2007).
34. He, X. C. et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nature genetics 36, 1117-1121, doi: 10.1038/ng1430 (2004).
35. Strube, A. et al. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clinical cancer research: an official journal of the American Association for Cancer Research 15, 3751-3759, doi: 10.1158/1078-0432.CCR-08-3123 (2009).
36. Katsuno, Y. et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27, 6322-6333, doi: 10.1038/onc.2008.232 (2008).
37. Ampuja, M. et al. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC cancer 13, 429, doi: 10.1186/1471-2407-13-429 (2013).
38. Liu, F. et al. Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification. Molecular imaging 7, 175-186 (2008).
39. Helms, M. W. et al. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptorpositive breast cancer. The Journal of pathology 206, 366-376, doi: 10.1002/path.1785 (2005).
40. Kakeda, M. et al. Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. Gene Ther 12, 852-856 (2005).